{"id":"https://openalex.org/W2182581691","doi":null,"title":"Cost analysis of therapy for patients with multiple sclerosis (MS) in Poland.","display_name":"Cost analysis of therapy for patients with multiple sclerosis (MS) in Poland.","publication_year":2008,"publication_date":"2008-09-01","ids":{"openalex":"https://openalex.org/W2182581691","mag":"2182581691","pmid":"https://pubmed.ncbi.nlm.nih.gov/19066409"},"language":"en","primary_location":{"id":"pmid:19066409","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19066409","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacological reports : PR","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069400338","display_name":"Arleta Matschay","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I120230055","display_name":"Poznan University of Medical Sciences","ror":"https://ror.org/02zbb2597","country_code":"PL","type":"education","lineage":["https://openalex.org/I120230055"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Arleta Matschay","raw_affiliation_strings":["Department of Pharmacoeconomics and Social Pharmacy, University of Medical Sciences in Pozna\u0144, Dabrowskiego 79, PL 60-529 Pozna\u0144, Poland","Department of Pharmacoeconomics and Social Pharmacy, University of Medical Sciences in Poznan, Dabrowskiego 79, PL 60-529 Poznan, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacoeconomics and Social Pharmacy, University of Medical Sciences in Pozna\u0144, Dabrowskiego 79, PL 60-529 Pozna\u0144, Poland","institution_ids":["https://openalex.org/I120230055"]},{"raw_affiliation_string":"Department of Pharmacoeconomics and Social Pharmacy, University of Medical Sciences in Poznan, Dabrowskiego 79, PL 60-529 Poznan, Poland","institution_ids":["https://openalex.org/I120230055"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042722940","display_name":"El\u017cbieta Nowakowska","orcid":"https://orcid.org/0000-0001-5515-9551","observed_orcids":["https://orcid.org/0000-0001-5515-9551"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elzbieta Nowakowska","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011707167","display_name":"Hanka Hertmanowska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I120230055","display_name":"Poznan University of Medical Sciences","ror":"https://ror.org/02zbb2597","country_code":"PL","type":"education","lineage":["https://openalex.org/I120230055"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Hanka Hertmanowska","raw_affiliation_strings":["Pozna\u0144 University of Medical Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pozna\u0144 University of Medical Sciences","institution_ids":["https://openalex.org/I120230055"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039682370","display_name":"Krzysztof Kus","orcid":"https://orcid.org/0000-0002-8838-3629","observed_orcids":["https://orcid.org/0000-0002-8838-3629"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Krzysztof Kus","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5028377811","display_name":"Anna Czubak","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna Czubak","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.6508,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":{"value":0.73320618,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"60","issue":"5","first_page":"632","last_page":"44"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.01730000041425228,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":1.0},{"id":"https://openalex.org/keywords/treatment-costs","display_name":"treatment costs","score":0.7730000019073486},{"id":"https://openalex.org/keywords/interferon-therapy","display_name":"interferon therapy","score":0.824999988079071},{"id":"https://openalex.org/keywords/interferon-beta-1b","display_name":"interferon beta-1b","score":0.7229999899864197},{"id":"https://openalex.org/keywords/corticosteroids","display_name":"corticosteroids","score":0.8360000252723694},{"id":"https://openalex.org/keywords/relapse-treatment","display_name":"relapse treatment","score":0.7720000147819519},{"id":"https://openalex.org/keywords/direct-and-indirect-costs","display_name":"direct and indirect costs","score":0.6650000214576721},{"id":"https://openalex.org/keywords/pharmacotherapy-costs","display_name":"pharmacotherapy costs","score":0.8450000286102295},{"id":"https://openalex.org/keywords/poland","display_name":"Poland","score":0.6949999928474426}],"concepts":[{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.8736288547515869},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.822839617729187},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.8210836052894592},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5155743956565857},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.42705225944519043},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.16839075088500977}],"mesh":[{"descriptor_ui":"D000068576","descriptor_name":"Interferon beta-1b","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003365","descriptor_name":"Costs and Cost Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004185","descriptor_name":"Disability Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006760","descriptor_name":"Hospitalization","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008279","descriptor_name":"Magnetic Resonance Imaging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008775","descriptor_name":"Methylprednisolone","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D008775","descriptor_name":"Methylprednisolone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009460","descriptor_name":"Neurologic Examination","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D011044","descriptor_name":"Poland","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016527","descriptor_name":"Drug Costs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016899","descriptor_name":"Interferon-beta","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D016899","descriptor_name":"Interferon-beta","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020529","descriptor_name":"Multiple Sclerosis, Relapsing-Remitting","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D020529","descriptor_name":"Multiple Sclerosis, Relapsing-Remitting","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D020529","descriptor_name":"Multiple Sclerosis, Relapsing-Remitting","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:19066409","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19066409","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacological reports : PR","raw_type":"Journal Article"},{"id":"mag:2182581691","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19066409","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W1580068662","https://openalex.org/W1964264880","https://openalex.org/W1987015847","https://openalex.org/W2001764506","https://openalex.org/W2005506388","https://openalex.org/W2006885721","https://openalex.org/W2018622875","https://openalex.org/W2019636638","https://openalex.org/W2027025693","https://openalex.org/W2032404313","https://openalex.org/W2033668765","https://openalex.org/W2042458479","https://openalex.org/W2043729729","https://openalex.org/W2051123512","https://openalex.org/W2061097019","https://openalex.org/W2078917422","https://openalex.org/W2101520046","https://openalex.org/W2105490558","https://openalex.org/W2112165124","https://openalex.org/W2112246282","https://openalex.org/W2131833895","https://openalex.org/W2134342836","https://openalex.org/W2145552726","https://openalex.org/W2155944588","https://openalex.org/W2159963451","https://openalex.org/W2165547142","https://openalex.org/W2312996869","https://openalex.org/W2313649737","https://openalex.org/W2318222824","https://openalex.org/W2340533542","https://openalex.org/W2417306299"],"related_works":["https://openalex.org/W1982811713","https://openalex.org/W2003521686","https://openalex.org/W2891825730","https://openalex.org/W2794875117","https://openalex.org/W2026069298","https://openalex.org/W1995844121","https://openalex.org/W2045134547","https://openalex.org/W3086605322","https://openalex.org/W2075715981","https://openalex.org/W53529533"],"abstract_inverted_index":{"Multiple":[0],"sclerosis":[1,58],"(MS)":[2],"is":[3],"a":[4],"neurological":[5],"disease":[6,26,36],"of":[7,65],"the":[8,30,45],"central":[9],"nervous":[10,39],"system":[11,40],"in":[12],"which":[13],"dissipated":[14],"demyelination":[15],"lesions":[16],"develop.":[17],"The":[18,42,87,95],"currently":[19],"available":[20],"pharmacotherapy":[21,96],"and":[22,34,38,47,75,79,109,115,123,131,137,145],"rehabilitation":[23],"for":[24,56,98,106,120,134],"this":[25],"aims":[27],"to":[28,141],"preserve":[29],"patients'":[31],"physical":[32],"abilities":[33],"prevent":[35],"progression":[37],"damage.":[41],"study":[43,88],"evaluated":[44],"direct":[46,130],"indirect":[48,132],"costs":[49,97,133],"associated":[50],"with":[51],"two":[52,63,92],"different":[53],"treatment":[54],"regimens":[55],"multiple":[57],"diagnosed":[59],"patients":[60,100],"by":[61],"comparing":[62],"groups":[64],"60":[66],"subjects":[67],"(Group":[68],"A--patients":[69],"receiving":[70,82],"continuous":[71],"interferon":[72],"therapy":[73],"(Betaferon)":[74],"steroids":[76],"during":[77],"relapses,":[78],"Group":[80,107,121,135,138],"B--patients":[81],"steroid-only":[83],"(Solu-Medrol,":[84],"Metypred)":[85],"treatment).":[86],"was":[89],"conducted":[90],"over":[91],"years":[93],"(2004-2005).":[94],"MS":[99],"were:":[101],"PLN":[102,110,116,124,142,146],"4,555,360.68":[103],"(1,171,043.88euro)":[104],"total":[105,119],"A":[108,136],"75,922.68":[111],"(19,517.40euro)":[112],"per":[113,127],"patient,":[114],"72,582.00":[117],"(18,658.61euro)":[118],"B":[122,139],"1,209.70":[125],"(310.98euro)":[126],"patient.":[128],"Total":[129],"amounted":[140],"5,595,968.58":[143],"(1,438,552.33euro)":[144],"1,655,658.30":[147],"(425,619.10euro),":[148],"respectively.":[149]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2016-06-24T00:00:00"}